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Introduction
The molecular basis for cancer is now well understood to in-
volve the genetic control of multiple genes that control cell cycle 
and tissue growth. The random mutations that activate dominant 
oncogenes or inactivate tumor suppression genes result in a cell 
cloning itself with an abnormal pattern of growth control forming 
a tumor. Traditional cancer therapies aim to destroy or remove 
the tumor by chemotherapy, radiation or surgery. The problem 
with both radiation and surgery is the ability of tumors to metas-
tasize and spread cancerous cells to areas inaccessible to these 
treatments or may not be noticeable at the time of treatment 
allowing a secondary tumor to appear. The trouble with chemo-
therapy is its low therapeutic index for many cancers and the 
rapid development of drug resistance in cancerous cells.
Gene therapy is a fundamentally different approach to the treat-
ment of diseases. Originally proposed as treatment for inherited 
autosomal recessive Mendelian disorders, such as hemophilia, 
gene therapy is now being used to treat multiple acquired condi-
tions including infections, degenerative diseases and cancer. Gene 
therapy is the use of genetic material (genes) to express a specific 
protein in a cell or to reduce the amount of protein by interfering 
with its synthesis. Replacing a defective gene with a functional 
one is the essence of gene therapy. 
Cancer is widely believed to arise from mutations to the cell’s 
DNA by either carcinogens or random mutations during cell 
division. This genetic basis coupled with the limitations of the 
traditional treatments, makes cancer a great candidate for gene 
therapies. More than 60 percent of all gene targeted therapy clin-
ical trials since 1989 aimed to treat cancer (Ginn et al, 2013). 
Strategies for Gene Therapy for Cancer
Cancer is a disease that involves multiple genetic changes to on-
cogenes, tumor-suppressor genes and modifier genes. There is 
also the intracellular interactions with multiple cells that regulate 
the body’s immune response and the interaction with other can-
cer cells to maintain a solid tumor. Gene therapy can be used 
alone or together with conventional treatments. It can be used 
to sensitize cancerous cells to radiation or chemotherapy. It can 
increase the body’s overall resistance to chemotherapy so larger 
doses can be used. Gene therapy can declump or shrink tumors 
to allow for surgical removal.  Various approaches are being ex-
amined both in preclinical studies and in clinical trials for gene 
therapy for cancer.
Downregulation of Genetic Targets
To downregulate the expression of protein coded by oncogenes, 
antisense molecules are used. Antisense molecules are synthet-
ic oligodeoxynucliotides (ODN) that hybridize with the coding 
(sense) mRNA of a specific gene. The antisense and sense mol-
ecules form double stranded RNA which cannot be translated 
destroying the mRNA. ODNs are designed to be highly resistant 
to nucleases which will destroy the mRNA (Stein et al., 1988). In 
a phase I–II clinical study using antisense ODNs to target BCL2 
(an anti-apoptotic oncogene) mRNA combined with chemother-
apy in patients with advanced malignant melanomas, the antisense 
ODN was found to successfully downregulate the target protein 
and has shown anti-tumor effects in 6 of the 14 patients (Jansen 
et al., 2000).
Immunomodulation by Gene Therapy
Because cancer cells originate from “self” cells, they generally do 
not cause a strong immune response. However, the immune sys-
tem can be augmented by gene therapy to increase their function. 
Therapeutic genes can be introduced into tumor cells or into 
effector cells such as T lymphocytes.
To elicit a greater immune response, tumor cells have been mod-
ified with the insertion of cytokine genes. Cytokines are small 
cell signaling polypeptides involved in immunity and inflammation. 
Systemic and local administration of cytokines from the interleu-
kin (IL) family has shown significant reduction in tumor size but 
have systemic side effects and short half-lives, making injection 
of interleukins deficient in long term tumor control. However, 
tumor cells modified to express IL-12 or IL-2 have shown the 
same size reduction as well as long term remission and metasta-
sis control (Gao et al., 2005, Tahara et al., 1995).
The receptors on T lymphocytes can be modified to target tu-
mor-associated antigens. The most common method of creating an 
artificial T cell receptor (TCR) is by protein fusion of single-chain 
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variable fragments derived from monoclonal antibodies that 
acts as the TCR ectodomain with the CD3-zetatransmembrane 
and endodomain. The endodomain can be further modified 
with co-stimulatory receptors to increase immunologic activity. 
Leukemias from B cell linages are suitable targets for this therapy. 
The CD19 antigen is expressed in differentiated cells with B cell 
linages and is rarely lost in cancerous cells. Anti-CD19 T cells can 
safely target and destroy cells expressing CD19 including can-
cerous cells, and they will later be replenished with healthy cells 
(Scheuermann & Racila, 1995).
For effective activation of T cells, non-specific signals are needed 
as well as the antigen-specific signal received by the T cell recep-
tor. Co-stimulatory molecules interact with receptors, such as 
CD28, on the T cell to provide the non-specific signals. Martinet 
et al. (2000) has shown that transfection of both IL-12 and 4-1BB 
ligand genes into tumor cells resulted in long-term remission 
of liver metastases in mice. The 4-1BB ligand, a co-stimulatory 
molecule that binds with the 4-1BB receptor on T cells, syner-
gizes with the CD28 pathway to increase the immune response 
(Melero et al., 1998). 
‘Suicide’ Gene Therapy
A commonly used idea for gene treatment of solid tumors is 
‘suicide’ gene therapy, where the cells expressing the therapeutic 
gene are killed. Suicide genes code for enzymes that can acti-
vate a drug with an otherwise low toxicity. When suicide genes 
are expressed only in the targeted cancer cells, the healthy cells 
avoid the drugs toxic effect. One enzyme commonly used is her-
pes simplex thymidine kinase, which converts the nontoxic drug 
Ganciclovir, into a toxic form by phosphorylation (Song et al., 
2009). The suicide gene can be placed under the control of tumor 
specific promoters such as c-erbB2 in breast cancer, ensuring spe-
cific drug activation in the tumor (Pandha et al., 1999). Because 
the enzyme can bleed into and kill neighboring non-transduced 
cells in what is termed the bystander effect, suicide genes can 
be optimized to only require ten percent transduction in a solid 
tumor greatly increasing its efficiency (Xiong et al., 2012). 
Apoptosis-inducing genes One of the problems involved in treat-
ing solid tumors by conventional therapies is that cancerous cells 
are often resistant to apoptosis and will not die with chemo-
therapy or radiation therapy alone. The gene that codes for the 
anti-tumor protein p53 is either mutated or deleted in more than 
50 percent of human tumors (Hollstein et al, 1991). Inserting a 
copy of wild type p53 into cancerous cells has been shown to 
induce apoptosis and make the cells more susceptible to chemo-
therapy and radiation therapy.
Anti-angiogenesis 
Tumors, just like any tissue, require a constant supply of nutrients, 
oxygen, hormones and growth factors for their growth and pro-
gression. This is provided by the formation of new blood ves-
sels or angiogenesis. Therefore, inhibition of angiogenesis would 
stunt tumor growth. Patients with glioblastoma multiforme, a 
highly vascularized form of brain cancer that does not respond 
well to conventional treatments, would benefit greatly from an 
anti-angiogenic treatment. Even poorly vascularized tumors can 
be reduced by anti-angiogenic treatment (Beecken et al., 2001). 
Clinical trials involving systemic administration of angiogenic in-
hibitors such as angiostatin and endostatin showed no dose-lim-
iting toxicity. However, they did not show marked signs of tumor 
regression due to the continuous release of pro-angiogenic 
factors released by the tumor (Ohlfest et al., 2005, Shepherd & 
Sridhar, 2003). Therefore, the delivery of angiogenic inhibitors by 
gene transfer is favored over systemic administration. 
Gene Transfer Techniques
The success of gene therapy lies in the efficient delivery of the 
gene of interest to the target cell. The therapeutic gene is cloned 
into a vector together with appropriate regulatory regions (pro-
moters/enhancers) as well as any supporting proteins needed. 
Selecting the right vector is a crucial part of gene therapy. The 
ideal vector will protect and easily deliver the genetic informa-
tion across the cell membrane and into the nucleus. It should 
have the ability to regulate the expression of the gene of interest 
and be able to successfully target specific cells to minimize toxic-
ity. It should be easy and inexpensive to produce in large quanti-
ties. Once the gene is cloned into the vector it can be introduced 
to the target cell. The gene can be delivered in vitro or in vivo. 
In in vitro transfer, cells from a specific tissue are removed from 
the patient and exposed to the gene-carrying vector. The trans-
formed cells are selected by biomarkers and are reintroduced 
into the patient’s body. In in vivo transfer, the vector is injected 
into the patient’s body directly, usually into the target tissue or 
the tumor if a tumor is the target.
Viral Vectors
Currently, the most effective method of gene transfer is though 
viral vectors. Viruses have evolved over the years to enter the cell 
and efficiently hijack the cell’s machinery to produce its own viral 
proteins. An ideal viral vector uses the viral infection pathway but 
avoids the expression of the viral genes that facilitate replication 
and the subsequent host cell death. This is achieved by deleting 
most of the viral genome, leaving intact the sequences (usually 
the long terminal repeats) required for capsid packaging and in-
tegration of the vector DNA into the host’s chromatin. The most 
commonly used viruses for gene therapy are retrovirus, lentivirus 
and adenovirus.
Retroviruses carry their genetic material as RNA and integrate 
their genome into host DNA using the viral enzymes reverse 
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transcriptase and integrase. The integrated DNA acts as a pro-
virus which replicates to make multiple copies of the virus and 
is released outside the cell. Therapeutic retroviral vectors are 
made replication-deficient by replacing the structural genes with 
the therapeutic gene. Since retroviruses only gain access to the 
host’s DNA when the nuclear membrane is broken down, they 
only infect actively dividing cells and integrate the gene of interest 
into the target cell.
Lentiviruses, a subclass of retroviruses, have recently been adapt-
ed to be used as gene transmission vectors. Lentivirus vectors 
can naturally enter an intact nuclear membrane and integrate 
their genome into non-dividing cells, which a retrovirus vector 
cannot do. HIV-1 is the most common lentivirus used in gene 
transfer. Because of its dangerous nature, lentivirus vectors do 
not carry the gene required for replication. As an added precau-
tion, self-inactivating (SIN) lentivirus vectors are being developed 
which contain deletions in the downstream LTR.
Adenoviruses carry their genetic material as double stranded 
DNA, but as opposed to the other viruses mentioned, the DNA 
is not integrated into the host’s genome. However, adenovirus 
can successfully infect broad range of cell type and is not limited 
to dividing cells. In 2003 the first gene therapy to be approved for 
commercial production was a recombinant adenovirus-p53 gene 
therapy for head and neck squamous cell carcinoma approved by 
China’s State Food and Drug Administration and is sold under 
the name Gendicine (Pearson et al., 2004).
Limitations of Viral Vectors
The obvious concern regarding the use of viral vectors is the 
possibility of the virus eliciting a strong immune response. In 
1999, an 18-year-old male died due to an extreme immune re-
sponse triggered by the administration of an adenoviral vector. 
He was participating in a phase I clinical trial to determine the 
safety of a gene therapy for ornithine transcarbamylase deficien-
cy, an X-linked genetic disease of the liver (Raper et al., 2003). 
Since then most work with adenovirus vectors used genetically 
crippled constructs which would minimize the likelihood of an 
immune response. 
The integration of the therapeutic gene when using retroviral 
or lentiviral vectors carries a possibility of oncogene activation. 
Since the point of insertion is mostly random, the transgene can 
insert into the upstream regulatory region of an existing gene 
and activate or upregulate the existing gene due to the proximity 
to the promoters in the downstream LTR of the transgene. The 
transgene can also insert itself into a transcriptional unit of an 
existing gene causing a loss of function in that gene. This was 
shown to be a real threat when four patients in a clinical trial that 
successfully treated X-linked severe combined immunodeficiency 
disease developed a form of leukemia. The cause in at least two 
of the patients appeared to be the integration of the therapeutic 
murine leukemia virus retroviral vector close to the LMO2 on-
cogene (Kohn et al., 2003). 
Adenovirus vectors, since they do not integrate the gene into the 
host’s genome, carry no risk of insertional mutagenesis. However, 
since adenovirus vectors to not integrate the gene into the cell’s 
DNA they are only expressed transiently and require multiple 
administrations to be effective and repeated delivery may com-
promise efficacy and might induce a severe immune response 
(Hartman et al, 2008). 
While self-inactivating (SIN) retroviral vectors may reduce the 
risk of insertional mutagenesis (Ellis, 2005), the clinical use of ret-
roviral vectors is curtailed due the limited packaging capacity of 
viral vectors. Most retroviral vectors can carry a transgene of up 
to 8 kb, as larger genes would compromise the efficiency of viral 
reverse transcription (Thomas et al,. 2003). This excludes the 
transport of multiple or large transgenes. Finally, the high costs 
involved in the manufacture of clinical-grade retroviral vector and 
regulatory issues keep viral vectors from widespread translation 
into clinical practice.
Non-viral Methods 
The simplest method of gene delivery is injecting naked DNA 
directly into the target tissue. Since naked DNA lacks any mode 
of transport through the cell membrane, there have been various 
methods developed to increase the efficiency of cellular uptake.
In smaller animals, hydrodynamic injection can overcome the low 
efficiency of cellular uptake. This procedure involves the injection 
of a large volume, about 10% the weight of the mouse, of DNA/
saline solution through the tail vein in less than 10 seconds, with 
most of the protein being expressed and accumulating in the liver 
(Liu et al., 1999). In larger animals, the volumes required for hy-
drodynamic injection become prohibitive. This limitation can be 
overcome by isolating an organ’s blood flow using catheters or 
part of a limb using external tourniquets.
The efficiency of delivery can be enhanced by physical methods 
such as microinjection directly into the cell, electroporation, so-
noporation and the use of microparticle in gene guns and mag-
netofection. Most of these methods are only feasible in in vitro 
gene delivery. Electroporation has been used successfully in gene 
delivery to mice skeletal muscle in vivo (Miyazaki et al., 2002), but 
the larger energy required to increase the permeability of the 
cell membrane across a human limb risks destroying too many 
cells. Sonoporation is limited to acoustically accessible organs. 
Although these methods are efficient, they require expensive 
specialized equipment reducing their benefit over viral vectors.
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The efficiency of delivery can also be increased by chemical 
methods. The negatively charged phosphate on DNA can bind 
to a variety of cationic polymers to form a DNA-polymer com-
plex called a polyplex. The polyplex interacts with the cell mem-
brane and is absorbed into the cell by phagocytosis where the 
polyplex is released and the DNA can migrate into the nucleus. 
Polyethylenimine (PEI) is one of the most commonly used non-vi-
ral vectors based on polycations for DNA delivery both in vitro 
and in vivo. PEI is a polymer with repeating units composed of an 
amine group and two carbon spacers. PEI can be linear, branched 
or as a highly branched dendrimer, though linear PEI is more 
commonly used. The exact mechanism my which the DNA-PEI 
polyplex escapes the endosome is unknown but is thought to 
be a result of the increased influx of protons, chloride ions, and 
water during endosome acidification causing it to rupture from 
the high osmotic pressure. Using confocal laser scanning micros-
copy, Merdan et al. (2002) observed the dispersal of the genetic 
cargo soon after the rupture of the endosomes  on living cells. 
Cationic lipids are also used to condense the DNA into a lipo-
some. These liposomes can protect the DNA from damage during 
transport, something that the other non-viral delivery methods 
fail to do.  Suzuki et al. (2010) successfully transfected murine 
ovarian tumors in vivo with IL-12 using self-prepared bubble lipo-
somes combined with ultrasound applied to the tumor. The bub-
ble liposome protocol was more effective than using the more 
expense commercially available transfection agent, Lipofectamine 
2000. However, the Lipofectamine control in the study was not 
conducted together with ultrasound.
Non-viral methods present many advantages over viral vectors. 
Most non-viral methods are simpler and cheaper to produce 
and elicit a smaller host immune response. The transfer capac-
ity of non-viral methods is functionally unlimited compared to 
viral capacity. Low levels of transfection used to be the limiting 
disadvantage, but advances have resulted in methods with trans-
fection rates that are clinically viable and can compete with viral 
vectors. However, the efficient delivery of DNA to the nucleus is 
not enough for long-term transgene expression if it cannot inte-
grate into the host genome. Transposable elements (transposons) 
could potentially offer such an alternative.
Transposon Systems for Gene Therapy
Transposons or transposable elements (TE) are mobile regions 
of DNA that can change their position in the genome. DNA 
transposons rely on a transposase enzyme to cut the TE from 
the donor site and insert it at the receiving site in a ‘cut-and-
paste’ like manner. The transposase gene is the trans-acting ele-
ment of the transposon system. The cis-acting element is a pair 
of inverted repeats at either end of the gene which are the target 
sites for the transposase as well as associated enhancers and 
promoters. Most regions coding for transposase also contain the 
cis-acting elements and are considered autonomous TEs. While 
transposons seem to have played a large role in evolution with 
close to fifty percent of the human genome made up of TEs, most 
species have accumulated mutations in the transposase genes.
One family of transposons, the mariner/tc1-like superfamily, has 
members in a wide range of species including nematodes, insects, 
fish, and humans with analogs reported in prokaryotes. This is a 
result of horizontal gene transfer between species. Unfortunately, 
not a single autonomous element has been isolated from verte-
brates. Ivics et al. (1997) reconstructed the first man-made trans-
poson system called the Sleeping Beauty (SB) transposon system 
based on the consensus sequence of members of the mariner/tc1 
family isolated from fish. The reconstructed SB transposase was 
successfully able to transfer elements not only in fish but also in 
other species including human cells. The use of a SB transposon 
based system of gene transfer was proposed in 2000 when suc-
cessful integration and long tern expression using SB was shown 
in mice (Yant et al., 2000).  
Because transposons have to survive along with the host cell, 
traits that posed less of a threat to the cell were selected evolu-
tionarily. A transposase with a high activity increases the chance 
of insertional mutagenesis. Therefore, early iterations of the SB 
tranposase had lower activity that could not compete with the 
fast acting retroviral enzymes. It was known early on that ex-
changing certain amino acids in SB transposase could increase its 
efficiency, but guessing the right combination of changes needed 
to construct a hyperactive transposase would be near impossible. 
Mates et al. (2009) conducted a large scale genetic screen of SB 
mutants and yielded a transposase (SB100X) that was ~100 times 
more efficient than first generation SB transposases. This hyper-
active transposase allows the SB transposon system to compete 
with viral vectors and was awarded the title of “Molecule of the 
Year, 2009. ”
Since SB transposon based vectors integrate the transgene into 
the host’s DNA, just as retroviral and lentiviral vectors do, they 
also pose the risk of insertional mutagenesis. Statistical analysis 
of the integration sites of both viral integrase and SB transposase 
suggests the SB vectors are safer. SB transposons integrate at 
TA dinucleotides and shows a preference (p<0.01) for a short 
TA palindromic consensus sequence. This preference can be 
explained by the greater bendability at TA sites that is possibly 
required to allow the transposase access, but with ~108 TA sites 
in the human genome this can still be considered random on a 
genomic level. A study mapping over 1,300 SB integration sites 
found 39 percent (p=0.02) integrated into known genes with a 
weak preference for regions slightly upstream or within 5kb of 
the start site (Yant et al., 2005). These results were compared to 
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10,000 computer-simulated insertions that showed truly random 
insertions would only result in 33 percent of genes. It is hard 
to avoid any preference for transcriptionally active genes since 
those are accessible due to chromatin modification such CpG 
islands. Even though SB transposon shows a statistically signifi-
cant preference for genes, the percentages are low compared to 
viral vector insertions.  Schröder et al. (2002) reported 69 per-
cent (p<0.0001) of in vivo integration sites using HIV-1 vectors 
were in known genes. Adding insulator sequences to the ends of 
transposable element can further reduce the risk of unwanted 
activation of neighboring genes (Walisko et al., 2007).
Long term expression of the transposase gene can result in the 
transposon being excised and reinserted in a different location in 
what is known as “re-hopping”, increasing the risk of insertional 
mutagenesis. To limit the amount of time in which transposase 
will be produced the transposase gene can transported on a sec-
ond plasmid that will be transcribed ectopically and destroyed. 
The use of mRNA as a source of transposase in also being ex-
plored (Wilber et al., 2006). 
The greatest weakness of the SB transposon system is its inability 
to infect cells. Any of the non-viral delivery methods mentioned 
above can be used to transport the SB-containing plasmid. There 
is also the possibility of using hybrid vectors that transport the 
transposon packaged into virions. These hybrid vectors may prove 
more effective than either method alone. The integration sites 
of an HIV-1/SB hybrid was shown to be closer to truly random 
integration profile with only 30 percent inserting into known 
genes (Staunstrup et al., 2009), and a herpes simplex virus/SB hy-
brid has successfully increased the capacity of the SB transposon 
(de Silva et al., 2009). SB transposon have also been successfully 
delivered to target tissue using modified liposomes that used 
Asialoglycoprotein receptor (ASGPR)-mediated endocytosis to 
target hepatocytes in vivo (Wang et al., 2009) and hybrid vectors 
may be employ similar targeting techniques being researched for 
viral vectors (Waehler et al., 2007).
Since transposons simply ‘cut-and-paste’, they do not have to rely 
on reverse transcriptase which has a tendency to incorporate 
mutations. The transposase can possibly be modified in the future 
to target a specific region of DNA using a synthetic zinc finger 
domain (Yant et al., 2007). SB transposons are easier and cheaper 
to manufacture than replication-incompetent viral vectors, allow-
ing researchers without the resources required to produce viral 
vectors to continue exploring transposon based systems.
Conclusion
Non-viral vectors with the ability to integrate the transgene are 
far more efficient than viral vectors or non-integrating DNA 
plasmids. The increase safety risks associated with viral vectors 
and resultant bureaucracy has limited the widespread use of 
commercially licensed gene therapy treatments. There are only 
two approved gene therapies worldwide in over 25 years of 
clinical trials, mostly due to safety and toxicity concern and not 
effectiveness. There is a need for a safer delivery system and the 
SB transposon system may be it. Most of its early limitations have 
been resolved to the point that it can compete with viral vectors. 
SB-mediated gene transfer has been shown to be effective in a va-
riety of treatment strategies including anti-angiogenesis (Ohlfest 
et al., 2005), suicide therapy (Song et al., 2009), and others. 
The first human clinical trial using SB transposons is under way. 
The trial will attempt to transfect T cells ex vivo with engineered 
receptors against the CD19 antigen as described above (Williams, 
2008). Regardless of what the results of this trial will be in terms 
of efficacy, the trial will prove the safety of this method and pro-
vide the data necessary for further improvement in future trials.  
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